KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have earned an average rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $27.2857.

Several research firms recently commented on KALV. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Thursday, December 4th. Citizens Jmp lowered their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research note on Tuesday, November 11th. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Citigroup reissued a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, October 8th.

Insider Buying and Selling

In related news, CEO Benjamin L. Palleiko sold 10,940 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $13.45, for a total transaction of $147,143.00. Following the sale, the chief executive officer owned 416,189 shares of the company’s stock, valued at $5,597,742.05. This trade represents a 2.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Paul K. Audhya sold 5,296 shares of KalVista Pharmaceuticals stock in a transaction on Monday, November 24th. The stock was sold at an average price of $13.45, for a total transaction of $71,231.20. Following the completion of the transaction, the insider directly owned 131,831 shares in the company, valued at $1,773,126.95. This represents a 3.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 31,329 shares of company stock valued at $437,371 over the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Tudor Investment Corp ET AL acquired a new stake in shares of KalVista Pharmaceuticals during the third quarter worth $24,360,000. Sherbrooke Park Advisers LLC purchased a new position in KalVista Pharmaceuticals in the 3rd quarter worth $191,000. Qube Research & Technologies Ltd lifted its position in KalVista Pharmaceuticals by 234.6% during the 3rd quarter. Qube Research & Technologies Ltd now owns 325,435 shares of the specialty pharmaceutical company’s stock worth $3,964,000 after acquiring an additional 228,187 shares during the period. Parkman Healthcare Partners LLC grew its stake in KalVista Pharmaceuticals by 155.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after purchasing an additional 1,055,940 shares during the last quarter. Finally, Brevan Howard Capital Management LP grew its stake in KalVista Pharmaceuticals by 319.1% during the 3rd quarter. Brevan Howard Capital Management LP now owns 55,878 shares of the specialty pharmaceutical company’s stock valued at $681,000 after purchasing an additional 42,545 shares during the last quarter.

KalVista Pharmaceuticals Trading Down 3.9%

KalVista Pharmaceuticals stock opened at $15.17 on Monday. KalVista Pharmaceuticals has a one year low of $7.30 and a one year high of $17.30. The business’s fifty day moving average is $13.62 and its 200 day moving average is $13.36. The stock has a market capitalization of $766.84 million, a PE ratio of -3.84 and a beta of -0.14. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.04. The firm had revenue of $13.69 million during the quarter, compared to analysts’ expectations of $6.03 million. On average, sell-side analysts predict that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.